Friday, 14 February 2014

Lixisenatide Resensitizes The Insulin-Secretory Response To Intravenous Glucose Challenge In People With Type 2 Diabetes – A Study In Both People With Type 2 Diabetes And Healthy Subjects

Lixisenatide thereby accelerates glucose disposal to nearly physiological intensity, and does not impair counter-regulation to low glucose levels by glucagon (Diabetes, Obesity and Metabolism)

No comments:

Post a Comment